Process for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor

a technology of hcmv glycoprotein and hcmv vaccine, which is applied in the field of process for the production of hcmv glycoprotein, antibodies thereto and hcmv vaccine, and recombinant vectors therefor, which can solve the problems of unsatisfactory side effects, unspecified total number of hcmv-specified glycoproteins, and uncertainty of the vaccine potential of individual glycoproteins

Inactive Publication Date: 2004-04-29
SMITH GEOFFREY LILLEY +2
View PDF5 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hitherto experimental vaccines have been based on attenuated, non-pathogenic forms of the virus, but these can have undesirable side effects.
However, the total number of HCMV-specified glycoproteins remains uncertain and the vaccine potential of individual glycoproteins is unknown.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
  • Process for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
  • Process for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

Identification of Putative Glycoprotein Genes

[0024] In order to look for possible glycoprotein genes within the HCMV genome individual cloned restriction fragments of the genome of HCMV strain AD169 were sequenced using the M13 / dideoxynucleotide chain termination method described in reference (11) using the strategy and methods described by Bankier and Barrell in reference (12). The resulting compiled sequences were then analysed for possible protein coding sequences and RNA polymerase II transcription signals. The predicted translation products of likely protein coding sequences were then examined for the presence of glycoprotein characteristics, namely an N-terminal hydrophobic signal peptide, a hydrophobic transmembrane sequence close to the C-terminus, and potential N-glycosylation sites in the external domain.

[0025] Using these criteria two putative glycoprotein genes were identified lying between bases 16255 and 18972 of the HindIII F fragment and between bases 228 and 2456 of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

HCMV glycoproteins B and H have been identified. The gB protein is encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F / D boundary. The gH protein is encoded by DNA in the HindIII L fragment lying between 228 and 2456 bases from the L / D boundary. The genes have been incorporated in recombinant vaccinia vectors and expressed in host animals to raise HCMV-neutralising antibody, thereby indicating vaccine potential. The glycoproteins can also be used in a variety of different ways, as vaccines or in the production, purification or detection of HCMV antibody.

Description

[0001] This invention relates to human cytomegalovirus (HCMV), and is concerned with the production of glycoproteins of the virus, their vaccine potential, and the production of HCMV specific antibodies.BACKGROUND TO THE INVENTION[0002] HCMV is a human pathogen of considerable importance and there is a demand for an effective vaccine against it. Hitherto experimental vaccines have been based on attenuated, non-pathogenic forms of the virus, but these can have undesirable side effects. The invention provides an alternative approach to the production of a vaccine against HCMV, using recombinant DNA techniques.[0003] Like other herpes viruses HCMV specifies multiple glycoproteins (1,2). Characterisation of these have involved studies of CMV-infected cells and purified virions using polyclonal sera and monoclonal antibodies (2-10). One glycoprotein has been partially purified and shown to elicit a neutralising response in guinea pigs. However, the total number of HCMV-specified glycopro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00C07K14/045C07K16/08
CPCA61K39/00C07K14/005C12N2710/16122C07K2319/00C07K16/088
Inventor SMITH, GEOFFREY LILLEYCRANAGE, MARTIN PATRICKBARRELL, BARCLAY GEORGE
Owner SMITH GEOFFREY LILLEY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap